Weekly Insulin: One Injection a Week and How to Use It Safely

Weekly insulin is now a reality for diabetes patients. On September 24, 2026, the diabetes community welcomed the second approved weekly insulin, efsitora alfa (Onswik), for adults with Type 2 diabetes. This follows the approval of icodec (Awiqli) by less than seven months. Eli Lilly reports this regimen slashes basal insulin injections from about 365 per year to just 52.

This offers immense relief for those fatigued by daily injections. Fewer injections do not mean less monitoring. The monitoring format simply changes, making Continuous Glucose Monitoring (CGM) systems essential.

Daily vs. Weekly Insulin: The Core Differences

Think of daily insulin like drinking a glass of water every day: a dosage error today can be corrected tomorrow. Weekly insulin is a massive tank filled once, leaking water very slowly over a full week. You cannot quickly drain excess water if you miscalculate.

Weekly insulin operates under distinct pharmacokinetic rules:

1. Extended bodily presence. The body needs about 8 days to clear half the icodec dose, and nearly 17 days for efsitora. Daily insulin clears in just 12 to 25 hours.

2. Delayed stabilization. Daily insulin stabilizes within a few days. Weekly insulin takes 3 to 4 weeks to reach steady-state levels. Dose adjustments do not show full effects the next day; they phase in slowly.

3. Prolonged hypoglycemia. If a dose exceeds bodily needs, blood sugar drops can last days, not hours. This remains the most critical factor.

Is the Hypoglycemia Risk Real?

Yes. We must state this clearly without exaggeration. Clinical trials, especially in Type 1 patients, showed severe hypoglycemic episodes were more frequent in some weekly insulin (icodec) users compared to daily insulin (degludec) users.

Professor Melanie Davies attributes this partly to high initial dosing, designed using daily insulin protocols without accounting for dose accumulation over the first few weeks. The weekly insulin concept is sound; the initiation and titration methods require adjustment. Extreme caution and strict monitoring during the initial phase are mandatory.

Simplified Comparison

Adjusting the Dose

The golden rule: evaluate the overall trend, never a single reading. A solitary high or low reading post-injection may be transient and should not dictate adjustments. Physicians evaluate fasting morning glucose trends over several consecutive days to formulate decisions. This adjustment remains strictly the physician’s responsibility, not the patient’s.

Managing Hypoglycemia

Hypoglycemia occurs when blood sugar drops below 70 mg/dL. Levels below 54 mg/dL indicate severe risk. With weekly insulin, active drug remains in the system for days; the risk can resurface hours after the initial treatment.

Mild to Moderate Hypoglycemia (Conscious, able to eat):

• Consume 15 to 20 grams of fast-acting sugar (glucose tablets or fruit juice).

• Test blood sugar after 15 minutes. Repeat if levels remain low.

• Once levels exceed 70 mg/dL, eat a snack containing complex carbohydrates.

• Maintain strict monitoring over the following hours and days. Blood sugar may drop again.

Severe Hypoglycemia (Confused or unconscious, requires assistance):

• Do not force food or liquids; choking is highly probable.

• Administer glucagon (injection or nasal spray) immediately and call emergency services.

• The patient requires hospital evaluation and potentially multi-day observation due to the insulin's long half-life.

• The physician will subsequently adjust the next dose, potentially reducing or delaying it.

Medical authorities mandate that glucagon be immediately accessible to all insulin users, and their close contacts must know how to administer it.

Are Fingerpricks Sufficient?

Morning fingerpricks remain an approved monitoring method. A CGM device is not legally mandatory for weekly insulin use. However, the practical gap is massive:

This distinction is critical for patients initiating or transitioning to weekly insulin, older adults, individuals with a history of hypoglycemia, and those suffering from hypoglycemia unawareness.

The Linx CGM Device

This compact sensor adheres to the skin, measures interstitial fluid glucose, and transmits data directly to a smartphone.

• Near-minute readings detailing glucose ascent/descent velocity.

• 15-day lifespan covering two complete weekly insulin cycles.

• MARD of roughly 8.66%. Lower numbers indicate higher accuracy, positioning this well among modern devices (consult manufacturer data for specific clinical trials).

• IP68 water resistance; safe for showering and swimming.

• Factory calibrated; zero fingerpricks required for calibration.

• Instant alerts for approaching low thresholds, essential during sleep.

Optimizing CGM with Weekly Dosing

1. Monitor morning glucose trends across multiple days.

2. Check mid-week patterns. Isolate nocturnal drops specifically on days 4, 5, or 6 post-injection.

3. Compare consecutive weeks. Assess if patterns improve or degrade following dose modifications.

4. Export the "Time in Range" report for your physician. This metric quantifies time spent in safe zones, driving precise clinical dialogue.

5. Avoid rapid correction doses. The device measures interstitial fluid, lagging behind capillary blood by several minutes.

6. Default to fingerpricks if symptoms contradict CGM readings. Capillary blood is the definitive reference.

Crucial Directives

• Limited Approval: Current US approval for weekly insulin exclusively covers adults with Type 2 diabetes. Onswik pens will launch there in the coming months.

• Type 1 Sensitivity: Weekly insulin is not a plug-and-play substitute for multiple daily injections in Type 1 diabetes without intense specialist oversight.

• Tool, Not Treatment: The device does not lower blood sugar. It visualizes systemic responses. Its value unlocks only when data drives calculated medical decisions.

• No Self-Adjustment: Never modify doses based on a curve or an article. Establish a written protocol with your physician defining exact action triggers.

The question has shifted from "Will it work?" to "How do we deploy it safely?" The answer requires continuous 14-day mapping to visualize systemic responses to each dose, giving physicians an empirical baseline for adjustments. The weekly injection removes the burden of daily memory. The CGM removes the burden of guesswork.

If considering or actively using weekly insulin, ask your physician at the next appointment: "Do I need a CGM to evaluate my dose?" If approved, request a Linx CGM sensor for an initial 15-day cycle and bring the exported report to your follow-up.

Legal Disclaimer: This content is for informational purposes only and does not constitute professional medical advice. Never initiate or modify weekly insulin regimens without direct physician oversight. Verify regional drug and device availability and regulatory approval before finalizing clinical decisions.